MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

ADMA Biologics Company Profile (NASDAQ:ADMA)

Consensus Ratings for ADMA Biologics (NASDAQ:ADMA) (?)
Ratings Breakdown: 1 Buy Rating(s), 1 Strong Buy Rating(s)
Consensus Rating:Strong Buy (Score: 3.50)
Consensus Price Target: $19.50 (181.39% upside)

Analysts' Ratings History for ADMA Biologics (NASDAQ:ADMA)
Show:
DateFirmActionRatingPrice TargetActions
3/24/2016Maxim GroupReiterated RatingBuy$24.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/9/2015Raymond JamesInitiated CoverageStrong-Buy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
12/8/2014OppenheimerInitiated CoverageOutperform$20.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for ADMA Biologics (NASDAQ:ADMA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/9/2016        
5/13/2016Q1($0.37)($0.43)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/23/2016Q415($0.47)($0.58)$30.00 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2015Q315($0.39)($0.48)$1.50 million$1.85 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2015Q215($0.36)($0.44)$1.50 million$1.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/12/2015Q115($0.38)($0.37)$1.50 million$1.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/9/2015($0.38)($0.38)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/10/2014($0.37)($0.36)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for ADMA Biologics (NASDAQ:ADMA)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.37)($0.37)($0.37)
Q3 20161($0.38)($0.38)($0.38)
Q4 20161($0.19)($0.19)($0.19)
(Data provided by Zacks Investment Research)
Dividend History for ADMA Biologics (NASDAQ:ADMA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for ADMA Biologics (NASDAQ:ADMA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
5/3/2016Adam S GrossmanCEOBuy200,000$6.50$1,300,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/3/2016Brian LenzCFOBuy2,500$6.50$16,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/3/2016James MondCMOBuy770$6.50$5,005.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/3/2016Jerrold B GrossmanDirectorBuy45,769$6.50$297,498.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/8/2015Adam S. GrossmanCEOBuy500$9.00$4,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/7/2015Jerrold B GrossmanDirectorBuy500$9.01$4,505.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2015Adam S GrossmanCEOBuy2,250$9.15$20,587.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2015Brian LenzCFOBuy1,000$9.15$9,150.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/2/2015Jerrold B GrossmanDirectorBuy6,000$9.16$54,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/1/2015Adam S GrossmanCEOBuy1,800$9.17$16,506.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/25/2015Adam S GrossmanCEOBuy1,800$9.18$16,524.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/20/2015Adam S GrossmanCEOBuy3,861$9.21$35,559.81View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/19/2015Adam S GrossmanCEOBuy2,000$8.50$17,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Adam S GrossmanCEOBuy5,500$7.98$43,890.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/17/2015Jerrold B GrossmanDirectorBuy500$8.01$4,005.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Adam S GrossmanCEOBuy8,800$8.03$70,664.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015James MondCMOBuy1,250$8.02$10,025.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/16/2015Lawrence P GuiheenDirectorBuy1,000$7.96$7,960.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/13/2015Eric I RichmanDirectorBuy3,500$7.88$27,580.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/12/2014Adam S GrossmanCEOBuy4,300$9.57$41,151.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/22/2014Adam S GrossmanCEOBuy1,000$9.50$9,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/14/2014Adam S GrossmanCEOBuy2,100$9.77$20,517.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2014Adam S GrossmanCEOBuy1,875$9.59$17,981.25View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/22/2014Adam S GrossmanCEOBuy4,226$8.15$34,441.90View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/15/2014Adam S GrossmanCEOBuy13,400$7.50$100,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2014Brian LenzCFOBuy1,000$7.50$7,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/14/2014James MondCMOBuy1,315$7.60$9,994.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/10/2013Jerrold B GrossmanDirectorBuy3,650$7.30$26,645.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for ADMA Biologics (NASDAQ:ADMA)
DateHeadline
06/17/16 02:18 PMADMA Biologics : to Present at the 2016 JMP Securities Life Sciences Conference
06/16/16 06:38 AMADMA Biologics to Present at the 2016 JMP Securities Life Sciences Conference - [GlobeNewswire] - RAMSEY, N.J., June 16, 2016-- ADMA Biologics, Inc., a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and ...
06/10/16 04:02 PMADMA BIOLOGICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote o -
06/02/16 10:56 AM7 North Jersey entrepreneurs named to EY annual list - "Just the nomination alone was enough." She said the company plans to go national in the next three years. Adam Grossman, ADMA Biologics Inc. (Ramsey) As director, president and chief executive officer of ADMA Biologics, Grossman wears plenty of hats.
06/02/16 10:56 AMStayinFront Life Sciences Mobile Cloud Solution Selected by ADMA Biologics as Part of Ongoing Commercialization Infrastructure Buildout - About ADMA Biologics, Inc. (ADMA) ADMA is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of Primary Immune Deficiency Disease (PIDD ...
06/01/16 01:35 PMADMA Biologics, Inc. :ADMA-US: Earnings Analysis: Q1, 2016 By the Numbers : June 1, 2016 -
05/30/16 05:34 PMPerformance at a Glance on ADMA Biologics, Inc. (NASDAQ:ADMA) - HNN - Performance at a Glance on ADMA Biologics, Inc. (NASDAQ:ADMA)HNNWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how ADMA Biologics, Inc. (NASDAQ:ADMA)'s stock has performed at various points in its past. Currently, the ...and more »
05/30/16 05:34 PMADMA Biologics Inc (NASDAQ:ADMA) Impact Score At 0 - RealistInvestor.com - ADMA Biologics Inc (NASDAQ:ADMA) Impact Score At 0RealistInvestor.comAlpha One explored various online articles released on ADMA Biologics Inc (NASDAQ:ADMA), and it set a daily sentiment score of 0.435 on the company. The entity has an algorithm in place to know stock sentiment on the share after exploring the content ...and more »
05/25/16 01:49 PMADMA BIOLOGICS (NASDAQ:ADMA) Institutional Investor Sentiment - Wall Street Hints and News - ADMA BIOLOGICS (NASDAQ:ADMA) Institutional Investor SentimentWall Street Hints and NewsADMA Biologics, Inc. is a late-stage biopharmaceutical firm that develops, makes and intends to market specialty plasma biologics for the treatment and prevention of infectious diseases. The company has a market cap of $86.75 million. The Firm is ...and more »
05/25/16 01:49 PMTarget Check and Stock Performance Recap ADMA Biologics Inc (NASDAQ:ADMA) - Wall Street Hints and News - Target Check and Stock Performance Recap ADMA Biologics Inc (NASDAQ:ADMA)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, ADMA Biologics Inc ...and more »
05/25/16 01:49 PMEarnings Review and Stock Rundown for ADMA Biologics Inc (NASDAQ:ADMA) - Wall Street Hints and News - Earnings Review and Stock Rundown for ADMA Biologics Inc (NASDAQ:ADMA)Wall Street Hints and NewsInvestors and analysts will be paying close attention when the company posts earnings results. Earnings numbers can provide insight into a company's overall profitability. Covering equity analysts are expecting ADMA Biologics Inc (NASDAQ:ADMA) to post ...and more »
05/21/16 01:33 PMBroker Outlook For ADMA Biologics Inc (ADMA) - Share Trading News - Broker Outlook For ADMA Biologics Inc (ADMA)Share Trading NewsBroker Outlook For ADMA Biologics Inc (ADMA). By Brenton Akerman / in US Broker Ratings / on Friday, 20 May 2016 08:03 AM / 0 Comments. The most recently updated broker views and price targets issued for ADMA Biologics Inc (ADMA) are below.
05/19/16 02:00 PMADMA: Additional Capital Raised; Plasma Center Collections Escalating -
05/19/16 01:34 PMShare Recap and Earnings Focus on ADMA Biologics Inc (NASDAQ:ADMA) - Wall Street Hints and News - Share Recap and Earnings Focus on ADMA Biologics Inc (NASDAQ:ADMA)Wall Street Hints and NewsAnalysts and investors are usually very focused on company earnings numbers when they are released. Company earnings are a good way to evaluate the profitability of the company. Presently, covering analysts are anticipating ADMA Biologics Inc ...and more »
05/14/16 07:50 AMBRIEF-Adma Biologics Q1 loss per share $0.43 - Reuters - BRIEF-Adma Biologics Q1 loss per share $0.43ReutersMay 13 Adma Biologics Inc : * Adma Biologics reports first quarter 2016 results. * Q1 revenue $2.1 million versus I/B/E/S view $2.2 million. * Q1 loss per share $0.43. * Q1 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S Source text for Eikon ...
05/14/16 07:50 AMADMA Biologics (ADMA) Recieves $4M in Capital Through Amended Loan and Security Agreement with Oxford Finance - StreetInsider.com - ADMA Biologics (ADMA) Recieves $4M in Capital Through Amended Loan and Security Agreement with Oxford FinanceStreetInsider.comADMA Biologics, Inc. (NASDAQ: ADMA) today announced that it has accessed an additional $4.0 million from its lender, Oxford Finance LLC (Oxford), made available through an amendment of the parties' existing loan and security agreement.Adma Biologics reports 1Q lossMoney MorningADMA Biologics Reports First Quarter 2016 ResultsVirtual-Strategy MagazineRamsey biopharmaceutical company says losses widened, while revenue roseNorthJersey.comall 4 news articles »
05/14/16 07:50 AMADMA Biologics (ADMA) Recieves $4M in Capital Through Amended Loan and Security Agreement with Oxford Finance - Claim your 2-week free trial to StreetInsider Premium here. ADMA Biologics, Inc. (NASDAQ: ADMA) today announced that it has accessed an additional $4.0 million from its lender, Oxford Finance LLC (Oxford), made available through an amendment of the parties ...
05/14/16 07:50 AMFunds to be Utilized to Advance Company’s RI-002 Commercialization Efforts and Expand Plasma Center Network - RAMSEY, N.J., May 13, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain ...
05/13/16 04:16 PMAdma Biologics reports 1Q loss -
05/13/16 04:05 PMADMA Biologics Reports First Quarter 2016 Results - [GlobeNewswire] - RAMSEY, N.J., May 13, 2016-- ADMA Biologics, Inc., a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and ...
05/13/16 03:05 PMADMA Biologics Further Enhances Cash Position by Securing $4.0 Million in Additional Capital Through Amended Loan and Security Agreement with Oxford Finance - [GlobeNewswire] - RAMSEY, N.J., May 13, 2016-- ADMA Biologics, Inc., a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and ...
05/10/16 08:10 AMCheck on Analyst Ratings ADMA Biologics Inc (NASDAQ:ADMA) - B.O.D.Y Confidential - Check on Analyst Ratings ADMA Biologics Inc (NASDAQ:ADMA)B.O.D.Y ConfidentialCovering Wall Street analysts have an average rating of 1 on shares of ADMA Biologics Inc (NASDAQ:ADMA). This Zacks Research number is compiled from analysts that they have taken into consideration. This consensus rating falls on a 1 to 5 scale. A 1 or ...and more »
05/10/16 08:10 AMPerformance Recap and Target Perspective on ADMA Biologics Inc (NASDAQ:ADMA) - B.O.D.Y Confidential - Performance Recap and Target Perspective on ADMA Biologics Inc (NASDAQ:ADMA)B.O.D.Y ConfidentialIn the latest trading session, shares of ADMA Biologics Inc (NASDAQ:ADMA) moved -0.98%. In order to gain some further insight on stock performance, we can take a look at the stock price relative to some moving averages. After a recent check, company ...and more »
05/07/16 07:35 AMADMA Biologics Inc (NASDAQ:ADMA): Director Grossman Jerrold B buys 45,769 shares - According to ADMA Biologics Inc's most recent Form 4 filing with the SEC dated May 05 07:25 PM, company Director, Grossman Jerrold B disclosed buying 45,769 shares at a cost of $6.50. At the time of this transaction (May 03), this trade was worth $297,499 ...
05/04/16 06:42 AMADMA Biologics Announces Full Exercise Of Underwriters' Option To Purchase Additional Shares - RAMSEY, N.J., May 03, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and prevention of certain ...
05/03/16 09:47 AMADMA Biologics Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares - [GlobeNewswire] - RAMSEY, N.J., May 03, 2016-- ADMA Biologics, Inc., a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and ...
05/02/16 10:35 AMADMA: Consistent Progress Toward RI-002 Approval -
05/02/16 08:16 AMAverage Analyst Rating for ADMA Biologics Inc (NASDAQ:ADMA) - B.O.D.Y Confidential - Average Analyst Rating for ADMA Biologics Inc (NASDAQ:ADMA)B.O.D.Y ConfidentialWall Street analysts have provided an average broker recommendation of 1 on ADMA Biologics Inc (NASDAQ:ADMA) shares. The rating is determined by using the average of all analyst recommendations taken into consideration by Zacks Research.and more »
05/02/16 08:16 AMMorning Alert: ADMA Biologics, Inc. (NASDAQ:ADMA), SeaDrill Limited (NYSE:SDRL), Incyte Corporation (NASDAQ ... - KC Register - Morning Alert: ADMA Biologics, Inc. (NASDAQ:ADMA), SeaDrill Limited (NYSE:SDRL), Incyte Corporation (NASDAQ ...KC RegisterADMA Biologics, Inc. (NASDAQ:ADMA) announced that it intends to offer shares of its common stock in an underwritten public offering. The company expects to grant the underwriters of the offering an option to purchase additional shares of common stock ...
04/29/16 08:43 AMBRIEF-ADMA Biologics prices offering of 1.89 mln common shares at $6.50/shr - Reuters - BRIEF-ADMA Biologics prices offering of 1.89 mln common shares at $6.50/shrReutersApril 28 ADMA Biologics Inc. * ADMA biologics announces pricing of public offering of common stock. * Says public offering of 1.89 million common shares priced at $6.50per share Source text for Eikon: Further company coverage: (Bengaluru Newsroom: +1 ...
04/29/16 08:43 AMADMA Biologics Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release) - ADMA Biologics Announces Proposed Public Offering of Common StockGlobeNewswire (press release)RAMSEY, N.J., April 27, 2016 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment and ...and more »
04/29/16 08:43 AMADMA Biologics (ADMA) Prices 1.89M Common Stock Offering at $6.50/Share - Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here. ADMA Biologics, Inc. (NASDAQ : ADMA) announced the pricing of its previously announced underwritten public offering of 1,892,308 shares of common stock at a public ...
04/28/16 04:01 PMADMA BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendment or Waiver to Code of E -
04/28/16 08:15 AMADMA Biologics Announces Pricing of Public Offering of Common Stock - [GlobeNewswire] - RAMSEY, N.J., April 28, 2016-- ADMA Biologics, Inc., a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment ...
04/27/16 03:37 PMADMA BIOLOGICS, INC. Files SEC form 8-K, Other Events -
04/27/16 03:05 PMADMA Biologics Announces Proposed Public Offering of Common Stock - [GlobeNewswire] - RAMSEY, N.J., April 27, 2016-- ADMA Biologics, Inc., a late-stage biopharmaceutical company that develops, manufactures, and intends to commercialize specialty plasma-based biologics for the treatment ...
04/27/16 09:35 AMShare Performance and Target Price Review ADMA Biologics Inc (NASDAQ:ADMA) - B.O.D.Y Confidential - Share Performance and Target Price Review ADMA Biologics Inc (NASDAQ:ADMA)B.O.D.Y ConfidentialDuring the most recent trading session, shares of ADMA Biologics Inc (NASDAQ:ADMA) ended up with a move of -2.40%. Sell-side analysts have given a consensus target price of $19.13 on company shares. Target price projections may differ greatly from ...and more »
04/27/16 09:35 AMAfter Last Week What Do Analysts Think Of ADMA Biologics Inc (ADMA) - Share Trading News - After Last Week What Do Analysts Think Of ADMA Biologics Inc (ADMA)Share Trading News05/18/2015 – ADMA Biologics Inc was upgraded to “buy” by analysts at Zacks. They now have a USD 9.5 price target on the stock. 12/08/2014 – Oppenheimer began new coverage on ADMA Biologics Inc giving the company a “outperform” rating. They now ...
04/22/16 09:05 AMADMA Biologics Inc (NASDAQ:ADMA) Share Rating Recap - The Post - ADMA Biologics Inc (NASDAQ:ADMA) Share Rating RecapThe PostShares of ADMA Biologics Inc (NASDAQ:ADMA) are tracked by analysts as well as crowd investors. Research from Beta Systems keeps track of crowd sourced sentiment and provides consensus stock ratings. The rating information comes mainly from ...and more »
04/21/16 09:09 AMADMA Biologics Inc (NASDAQ:ADMA) Has An Average Rating Of 5 - Investor Newswire - ADMA Biologics Inc (NASDAQ:ADMA) Has An Average Rating Of 5Investor NewswireAlpha One uses algorithm-based analytics to know about a stock sentiment varying as per the published content on online channels. In this analysis, the group considers only the most relevant news sources on a daily basis. ADMA Biologics Inc ...and more »
04/20/16 09:33 AMLatest Analyst Ratings For ADMA Biologics Inc (ADMA) - Share Trading News - Latest Analyst Ratings For ADMA Biologics Inc (ADMA)Share Trading News09/09/2015 – Raymond James began new coverage on ADMA Biologics Inc giving the company a “strong-buy” rating. They now have a USD 15 price target on the stock. 05/18/2015 – ADMA Biologics Inc was upgraded to “buy” by analysts at Zacks. They now ...
04/19/16 09:32 AMCheck on Stock Rating ADMA Biologics Inc (NASDAQ:ADMA) - Business Standard Tribune - Check on Stock Rating ADMA Biologics Inc (NASDAQ:ADMA)Business Standard TribuneADMA Biologics Inc (NASDAQ:ADMA) currently has a rating of 1 on shares. On a scale from 1 to 5, a rating of 1 or 2 would represent a Buy. On the same scale, a stock rating of 4 or 5 would represent a Sell. A rating of 3 would represent a Hold. This ...and more »
04/17/16 07:37 AMiPlay America to Host NJBIZ Best Places to Work in New Jersey Awards - The following businesses will be honored for ranking in the Top 100 during the 2016 Best Places to Work in New Jersey: Small & Medium Companies (15-249 employees) ADMA Biologics, Inc., AEPG Wealth Strategies, AmeriHealth New Jersey, Applegate ...
04/15/16 12:04 PMADMA Biologics Inc (NASDAQ:ADMA): Quick Look at Earnings - News Tribune - ADMA Biologics Inc (NASDAQ:ADMA): Quick Look at EarningsNews TribuneWhen ADMA Biologics Inc (NASDAQ:ADMA) issues their next quarterly report on or near 2016-05-10, Wall Street analysts are predicting they will report earnings per share of $-0.48. This consensus EPS number is provided by Zacks Research, which might ...and more »
04/15/16 12:04 PMAdma Biologics Incorporated (NASDAQ:ADMA) Shorted Shares Increased 48.64% After Market Selling - RiversideGazette.com - Adma Biologics Incorporated (NASDAQ:ADMA) Shorted Shares Increased 48.64% After Market SellingRiversideGazette.comADMA Biologics, Inc. is a biopharmaceutical firm that develops and makes specialty plasma biologics for the treatment and prevention of certain infectious diseases. The company has a market cap of $81.12 million. The company's targeted patient ...Broker Roundup For ADMA Biologics Inc (ADMA)Share Trading Newsall 2 news articles »
04/14/16 01:27 PMADMA Biologics Inc (NASDAQ:ADMA) Analyst Recommendation Outlook - Clinton Financial - Clinton FinancialADMA Biologics Inc (NASDAQ:ADMA) Analyst Recommendation OutlookClinton FinancialThere are 5 analysts providing ratings for ADMA Biologics Inc (NASDAQ:ADMA). 5 have given the stock a “Strong Buy”, 0 rate it a “Buy”, 0 are rating the stock a Hold, and 0 are recommending “Sell”. Every recommendation can be mapped to an integer based ...and more »
04/13/16 02:07 PMHow Many ADMA Biologics Inc (NASDAQ:ADMA)'s Analysts Are Bullish? - RiversideGazette.com - How Many ADMA Biologics Inc (NASDAQ:ADMA)'s Analysts Are Bullish?RiversideGazette.comOut of 4 analysts covering ADMA Biologics (NASDAQ:ADMA), 6 rate it “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. ADMA Biologics was the topic in 2 analyst reports since September 9, 2015 according to StockzIntelligence Inc. Below is a ...
04/13/16 02:07 PMEarnings Watch on ADMA Biologics Inc (NASDAQ:ADMA) - RiversideGazette.com - Earnings Watch on ADMA Biologics Inc (NASDAQ:ADMA)RiversideGazette.comADMA Biologics Inc (NASDAQ:ADMA) has a consensus earnings per share estimate for the current quarter of $-0.48 based on compiled analyst projections. The company is next expected to release earnings on or around 2016-05-10 for the period ending ...and more »
03/29/16 04:12 PMADMA BIOLOGICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement -
03/29/16 12:04 PMADMA BIOLOGICS, INC. Financials -
About ADMA Biologics

ADMA Biologics logoADMA Biologics, Inc. is a biopharmaceutical company that develops and manufactures specialty plasma-based biologics for the treatment and prevention of certain infectious diseases. The company's targeted patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disorder or who may be immune-suppressed for medical reasons. The Company's lead product candidate, RI-002, is intended for the treatment of primary immune deficiency disease (PIDD). RI-002 is an injectable immune globulin derived from human plasma, with levels of naturally occurring polyclonal antibodies, as well as levels of antibodies targeted to respiratory syncytial virus (RSV). The company's RI-002 demonstrated Phase III results and attained its primary endpoint and preliminary analysis indicates that the treatment with RI-002 resulted in no serious bacterial infections (SBI's) observed in study subjects during the trial.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ADMA
  • CUSIP:
Key Metrics:
  • Previous Close: $6.93
  • 50 Day Moving Average: $6.80
  • 200 Day Moving Average: $6.66
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $89.30M
  • Current Quarter EPS Consensus Estimate: $-1.02 EPS
Additional Links:
ADMA Biologics (NASDAQ:ADMA) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha